News
Novel Stroke biosignature and machine learning model identified for greatest diagnostic accuracy through blood samples
In a close collaboration with a prestigious Austin, TX medical center, InSyBio applied its proprietary technology to identify targeted biomarkers to provide an unbiased, non-interventive diagnostic method for Stroke. This is incredibly important when making clinical decisions in such a time-sensitive situation as stroke, where blood biomarkers could aid in faster diagnosis and treatment. Classifying… Continue reading→
Team VIRTUOUS: InSyBio pioneering precision nutrition through European funded project
In conjunction with a prestigious team of researchers and industry, InSyBio has been awarded funding under the Marie Skłodowska-Curie Research and Innovation Staff Exchange (RISE) for precision nutrition. Benefiting industry and academia worldwide, the team will work to design an intelligent “virtual tongue” (VIRTUOUS) capable of taste prediction. Through the integration of drug discovery techniques,… Continue reading→
InSyBio taking steps to help tackle the opioid crisis through precision medicine
In an effort to find a better alternative to the traditionally prescribed opioid analgesics, InSyBio worked in collaboration with Clarity Science and the OPERA study (Optimizing Patient Experience and Response to Topical Analgesics) to utilize advanced machine learning methods to not only predict patient response to treatment but also to stratify chronic pain patients into individuals who will… Continue reading→
InSyBio awarded on Ignite Ideas program organised by Nestle Hellas
InSyBio has been recently awarded for its superior performance in the context of the Ignite Ideas program (https://igniteideas.gr/en/) which was organised by Nestle Hellas. InSyBio has participated in this program, with its revolutionary idea of personalizing the coffee blend and type selection combining input from a saliva test and responses to questionnaires in order to… Continue reading→
InSyBio Suite V2.5 has been launched and Includes for the first time a complete pipeline for the analysis of RNA-sequencing data
The new version of InSyBio Suite enables the fast and accurate discovery of transcriptomics predictive biomarkers. InSyBio Suite version 2.5 has been officially launched as of Monday May 9th, 2019. The Chief Scientific Officer of InSyBio, Dr. Seferina Mavroudi, stated that “Our transcriptome contains information combining our genetic predisposition and more advanced epigenetic mechanisms. With the new… Continue reading→
InSyBio reveals novel diagnostic and prognostic biosignature for Glioblastoma and announces its presentation at the 11th annual RECOMB/ISCB Conference on Regulatory & Systems Genomics
InSyBio’s R&D team applying the company’s proprietary predictive biomarker technology to a collection of data from open omics repositories came up with a novel biosignature of 13 transcripts and a predictive model for glioblastoma diagnosis and treatment. The biosignature not only increases significantly the diagnostic accuracy for glioblastoma but it is able to differentiate it from other types of… Continue reading→
InSyBio Suite V2.4 has been launched and includes for the first time the InSyBio Biomarkers Tool
The new version of InSyBio Suite has a significant increase in speed and refinement of the predictive biomarkers process. InSyBio Suite version 2.4 has been officially launched on Monday 26th of November 2018. The Chief Scientific Officer of InSyBio, Dr. Seferina Mavroudi, stated that “At InSyBio we are crazy enough to think that we can revolutionize the… Continue reading→
InSyBio makes the big step to the USA biotechnology market with the help of International Accelerator!
InSyBio is the latest startup company to join the International Accelerator program in Austin, Texas USA (https://www.internationalaccelerator.com/) with an ultimate goal to get access to the USA biotechnology market. Labros Digonis, the CEO of InSyBio, who holds a MBA and Master’s Degree in Naval Architecture & Marine Engineering and has over 30 years of experience… Continue reading→
InSyBio wins the Investor Prize in the category of Big Data for Health in Sanofi’s Labs in the VivaTech 2017 event
We are proud to announce that InSyBio is the winner of the Investor Prize in the category of Big Data for Health in Sanofi’s “Tech for health” Lab in VivaTech 2017 event (https://vivatechnology.com/) which was held at Paris, 15-17 June, 2017. InSyBio was one of the 34 innovative companies sponsored by Sanofi to join the Viva Technology… Continue reading→